Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
UK researchers uncover first new asthma and COPD attack treatment in 50 years
The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings
Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children
The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme
Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation
JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants
FDA approves updated COVID-19 vaccines to better protect against current variants
Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older
UK study reveals previously unknown genetic causes of colorectal cancer
The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year
JCVI announces advice for autumn COVID-19 vaccination programme eligibility
The Committee has advised offering the vaccine to those at high risk of serious disease
Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk
Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years
Novo Nordisk’s Ozempic associated with cognitive benefits in diabetes patients
Researchers from the University of Oxford analysed records from more than 100 million patients in the US
Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP
The vaccine generated an improved response against several Omicron JN.1 sublineages
AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients
Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths
Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients
Approximately 90% of patients who received a third dose developed significant levels of antibodies
Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn
The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines